Axsome Therapeutics, Inc.
DE ˙ DB ˙ US05464T1043
199,30 € ↑9,50 (5,01%)
2026-06-04
AKTIENPREIS
SecurityDE:19X / Axsome Therapeutics, Inc.
InstitutionTorray Llc
Latest Disclosed Ownership14,774 shares
Latest Disclosed Value $ 2,497,101
Torray Llc reports 0.14% decrease in ownership of 19X / Axsome Therapeutics, Inc.

On May 1, 2026 - Torray Llc filed a 13F-HR form disclosing ownership of 14,774 shares of Axsome Therapeutics, Inc. (DE:19X) valued at $2,072,792 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 28, 2026 disclosing 14,794 shares of Axsome Therapeutics, Inc.. This represents a change in shares of -0.14% during the quarter. The current value of the position is $2,944,458 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-01 2026-03-31 13F Axsome Therapeutics COM 05464T104 14,774 -20 -0.14 2,497 -7.55 0.3663
2026-01-28 2025-12-31 13F Axsome Therapeutics COM 05464T104 14,794 -2,625 -15.07 2,702 27.71 0.3869
2025-10-22 2025-09-30 13F Axsome Therapeutics COM 05464T104 17,419 354 2.07 2,116 18.75 0.2870
2025-08-05 2025-06-30 13F Axsome Therapeutics COM 05464T104 17,065 -51 -0.30 1,781 -10.77 0.2586
2025-05-08 2025-03-31 13F Axsome Therapeutics COM 05464T104 17,116 -58 -0.34 1,996 37.37 0.2974
2025-02-06 2024-12-31 13F Axsome Therapeutics COM 05464T104 17,174 5,351 45.26 1,453 36.82 0.2084
2024-11-05 2024-09-30 13F Axsome Therapeutics COM 05464T104 11,823 76 0.65 1,063 12.38 0.1487
2024-08-06 2024-06-30 13F Axsome Therapeutics COM 05464T104 11,747 1,209 11.47 946 12.50 0.1413
2024-05-10 2024-03-31 13F/A-1 Axsome Therapeutics COM 05464T104 10,538 10,538 841 0.1259
2024-05-09 2024-03-31 13F Axsome Therapeutics COM 05464T104 6,359 6,359 841 0.1259
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.